Obesity in 21-hydroxylase deficient patients
Authors:
- Peter C HindmarshPHPeter C Hindmarsh
- Charles G D BrookCBCharles G D Brook
Open Access
- 1 March 1998
- journal article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 78 (3) , 261-263
Abstract
OBJECTIVES To evaluate the natural history and timing of adiposity rebound (nadir of body mass index (BMI)) in children with congenital adrenal hyperplasia 21-hydroxylase deficiency (CYP21). STUDY DESIGN A retrospective mixed longitudinal study. METHODS Height and changes in body composition (BMI; weight (kg)/height2 (m)), triceps and subscapular skinfolds) were analysed in 22 (14 girls, eight boys) prepubertal patients with CYP21 for whom continuous anthropometric data were available for at least seven years. BMI and height SD scores were compared at 1, 5, and 10 years of age. Skinfold SD scores were compared at 2.5 and 5.5 years. Thirteen children (nine girls, four boys) had records available from birth which allowed the estimation of the age at adiposity “peak” and “rebound”. RESULTS A significant increase in BMI SD score was found at 5 and 10 years compared with those at 1 year. No significant change in height SD score was observed at these ages. Triceps and skinfold SD score were increased significantly at 5.5 compared with 2.5 years. The “rebound” in BMI SD score took place at 1.74 years (range 0.71–4.57 ) compared with 5.5 years (range 3.5–7.0) in the normal UK population. CONCLUSIONS Normally growing patients with CYP21 increased their BMI throughout childhood. Adiposity rebound took place on average three years earlier than in the general population. These findings suggest that even when well controlled in terms of their disease process, patients with CYP21 are at risk of obesity, which may have important implications for the evolution of reproductive function (polycystic ovaries), diabetes, hypertension, and cardiovascular disease in these subjects.Keywords
This publication has 9 references indexed in Scilit:
- Hydrocortisone replacement therapy in children and adolescents with hypopituitarismClinical Endocrinology, 1997
- Growth Pattern during the First 36 Months of Life in Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)Hormone Research, 1997
- The use of adrenalectomy as a treatment for congenital adrenal hyperplasia.The Journal of Clinical Endocrinology & Metabolism, 1996
- The use of adrenalectomy as a treatment for congenital adrenal hyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 1996
- Adult height in women with early‐treated congenital adrenal hyperplasia (21‐hydroxylase type): relation to body mass index in earlier childhoodActa Paediatrica, 1995
- Body mass index reference curves for the UK, 1990.Archives of Disease in Childhood, 1995
- Monitoring treatment in congenital adrenal hyperplasia.Archives of Disease in Childhood, 1989
- Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy.1988
- Adiposity rebound in children: a simple indicator for predicting obesityThe American Journal of Clinical Nutrition, 1984